Insomnia and somnolence in idiopathic RBD: a prospective cohort study

Ronald B. Postuma1,2, Jean-François Gagnon2,3, Amelie Pelletier2 and Jacques Y. Montplaisir2,4

Although some sleep disorders are markers of prodromal Parkinson’s disease and dementia with Lewy bodies, it is unclear whether insomnia and somnolence can predict disease. We assessed a large cohort of patients with idiopathic rapid eye movement sleep behavior disorder and age/sex matched controls, comparing the Epworth sleepiness scale, the Insomnia Severity Index, the Pittsburgh Sleep Quality Index, and polysomnographic variables. In those with repeated scales, we assessed change over time. Finally, we assessed whether sleep abnormalities predicted defined neurodegenerative disease. The 151 patients (age = 65.9, 75% male) completed sleep scales and were included. Eworp scores were similar between patients and controls (7.0+/−4.6 vs. 7.2+/−4.7, p = 0.77), and did not progress with time (change = +0.46+/−2.1, p = 0.45). Eworp scores were similar between those who developed neurodegenerative disease and those remaining disease-free (6.7+/−4.4 vs. 7.1+/−4.7, p = 0.70). Pittsburgh Index scores were higher in patients than controls (7.2+/−3.8 vs. 4.9+/−3.4, p = 0.004), mainly driven by the sleep disturbance/medication components (reflecting rapid eye movement sleep behavior disorder symptoms/treatment). Baseline Pittsburgh scores did not predict conversion to neurodegeneration, although sleep duration increased over time in those converting to neurodegenerative disease (+0.88+/−1.32 h, p = 0.014). Insomnia index scores were higher in patients than controls (10.0+/−5.5 vs. 6.35+/−4.66, p < 0.001), but declined over time (−1.43+/−5.09, p = 0.029) particularly in those converting to neurodegenerative disease. Finally, on polysomnogram, those with increased tonic rapid eye movement had higher risk of developing defined neurodegenerative disease (HR = 1.88, p = 0.039). In summary, we found that somnolence and insomnia do not predict neurodegeneration in idiopathic rapid eye movement sleep behavior disorder. As neurodegeneration progresses through prodromal stages, patients may have increasing sleep drive and duration.

npj Parkinson’s Disease (2017) 3:9; doi:10.1038/s41531-017-0011-7

INTRODUCTION

Daytime somnolence and insomnia are common features of neurodegenerative synucleinopathies. Insomnia, particularly sleep maintenance insomnia, occurs in up to 50% of Parkinson’s disease (PD) patients and is a common early feature of disease.1 Somnolence occurs in 30–40% of PD and 40–70% of dementia with Lewy bodies (DLB), and becomes more common as disease progresses.2 Although onset time varies, both sleep disorders can be seen at diagnosis, suggesting that they may be present in prodromal disease.

So far, however, evidence for somnolence and insomnia as prodromal markers is limited. Two general population studies reported that increased daytime sleep was associated with a 2–3 fold increased risk of developing PD in the future.3, 4 However, studies of early untreated PD have generally failed to find excessive daytime somnolence compared to controls.5, 6 For insomnia, a single study suggested a possible mild increased in PD risk (RR = 1.4) in those presenting to medical attention for insomnia in the prior two years,7 but no other studies have assessed whether insomnia predicts PD.

Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is the strongest known predictor of PD and other synucleinopathies.8 Long-term studies suggest that over 80% of idiopathic RBD patients will eventually develop neurodegenerative synucleinopathy.9–11 Therefore, following patients with idiopathic RBD allows a unique opportunity to directly observe the prodromal stages of disease, and to test potential prodromal markers. RBD patients have been used to establish predictive value of many prodromal markers, including hyposmia, dopaminergic functional neuroimaging, impaired color vision, REM sleep atonia loss, autonomic symptoms, EEG slowing and quantitative motor testing.12–18 A single study of patients with idiopathic RBD found that Epworth sleepiness scale (ESS) scores were higher than healthy controls and predicted faster conversion to neurodegeneration in RBD.19 However, no other studies have assessed whether insomnia or somnolence predict outcome in idiopathic RBD.

Since 2004, we have been following a large cohort of idiopathic RBD20 patients. As part of clinical follow-up, patients completed sleep scales including the ESS, the insomnia severity index (ISI), and the Pittsburgh Sleep Quality index (PSQI). Therefore, in this study, we assessed whether insomnia and somnolence severity could predict development of defined neurodegenerative synucleinopathy in idiopathic RBD, and measured the evolution of these sleep disorders during prodromal stages in those who eventually developed neurodegenerative disease.

1Department of Neurology, McGill University, Montreal General Hospital, Montreal, QC, Canada; 2Centre d’étude du sommeil et des rythmes biologiques, Hôpital du Sacré-Cœur de Montréal Montréal, 5400 Boul. Gouin Ouest, Montréal H4J 1C5 QC, Canada; 3Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada and 4Department of Psychiatry, Université de Montréal, Montreal, QC, Canada

Correspondence: Jacques Y. Montplaisir (JY.Montplaisir@umontreal.ca)

Received: 27 October 2016 Revised: 2 February 2017 Accepted: 11 February 2017

Published online: 20 March 2017
RESULTS
Participant characteristics
In total, we evaluated 158 patients with idiopathic RBD. The 151 patients had at least one baseline sleep analysis and were included in this analysis. Mean age was 66.4+/−8.3, RBD duration from symptom onset was 8.7+/−9.3 years, and 75% were male. Mean age of controls was 68.9+/−8.5 and 74% were male.

Of the 151 included in this analysis, the 132 had at least one annual follow-up examination, of whom 50 developed neurodegenerative disease after a mean interval of 3.2+/−8.5 years from baseline examination (range = 1–11 years). The 26 patients had a primary diagnosis of dementia, of whom 24 had at least one cardinal manifestation of parkinsonism and 15 had full International Parkinson and Movement Disorders Society (MDS) parkinsonism criteria at disease diagnosis. Twenty four had a primary diagnosis of parkinsonism, of whom 20 had PD and three had multiple system atrophy.

Epworth sleepiness scale
The 116 idiopathic RBD patients had a baseline ESS performed (Table 1). This was conducted on average 2.6+/−2.1 years before the most recent visit (for disease-free patients), or disease diagnosis (convertors). The mean ESS score was similar between idiopathic RBD patients (7.0+/−4.6) and controls (7.2+/−4.7, n = 57, p = 0.77). The proportion with abnormal ESS also did not differ (28.7% vs. 28.1%, p = 1.0).

104/116 patients had at least one prospective follow-up visit (Fig. 1, Table 1). We found no difference in baseline ESS scores between those who eventually converted and those still remaining disease-free (6.7+/−4.4 in convertors vs. 7.1+/−4.7 in disease-free, p = 0.70).

The ESS was repeated in 56 RBD patients at a mean interval (i.e. first to most recent score) of 2.3 years (Table 2). We found no change in ESS scores (average change = +0.07+/−3.1 points, p = 0.99). Moreover, there was no progression in ESS scores over time in those destined to develop disease (mean change = +0.46+/−2.1 points, p = 0.45).

Insomnia severity index
A total of 111 patients had assessment of their ISI, conducted an average of 2.6 years before last follow-up or disease diagnosis (Table 1). Overall, the mean ISI score in patients with idiopathic RBD was higher than controls (10.0+/−5.5 vs. 6.35+/−4.66, n = 54, p < 0.001). The 48.7% of RBD patients had abnormal ISI compared to 24.5% of controls (p = 0.004). When looking at specific items, differences were more marked for general sleep disturbances/ worry/impact (i.e. questions 4–7) than for the direct insomnia questions. Nevertheless, there was a modest significant increase in sleep maintenance insomnia in RBD patients compared to controls (questions 2+3 = 2.7+/−1.7 vs. 2.1+/−1.4, p = 0.043).

Of the 111 patients with ISI, 100 had at least one follow-up examination (Fig. 1, Table 1). There was no difference in baseline ISI between those who developed disease vs. those who remained disease-free (10.4+/−5.9 vs. 10.0+/−5.4, p = 0.76). Neither was there any difference in the scores of any single ISI item. The 63 patients who had a repeated ISI, at a mean interval of 3.0 years between first and most recent score (Table 2). We observed a significant decline in ISI over time (mean change = −1.43+/−5.09, p = 0.029), moving towards control values with time. Although this declined both in those developing disease and those still disease-free, this was more clearly seen in those with disease (−2.00 in disease converters vs. −1.16 in disease-free). When looking at subcomponents of the ISI in all RBD patients, the score reduction was primarily driven by questions related to sleep satisfaction/ worrying about sleep. However, there was a borderline decline in sleep maintenance insomnia scores (questions 2 and 3) in those who developed disease (change = −0.45+/−1.05 points, p = 0.083).

Table 1. Baseline sleep scale scores

|                      | Control (n = 57) | Idiopathic RBD (n = 116) | Disease-free (n = 71) | Converted (n = 33) | p     |
|----------------------|-----------------|--------------------------|-----------------------|-------------------|-------|
| Epworth Sleepiness   | 7.2+/−4.7       | 7.0+/−4.6                | 7.1+/−4.7             | 6.7+/−4.4         | 0.70  |
| Abnormal Epworth     | 28.7%           | 28.1%                    | 1.0                   | 27.8%             | 0.65  |
| Insomnia Severity    | 6.4+/−4.7       | 10.0+/−5.5               | <0.001                | 10.4+/−5.9        | 0.76  |
| Abnormal ISI         | 24.5%           | 48.7%                    | 0.004                 | 50.8%             | 0.65  |
| Onset Insomnia       | 0.74+/−0.91     | 0.86+/−1.04              | 0.47                  | 0.80+/−1.01       | 0.32  |
| Maintenance Insomnia | 2.11+/−1.39     | 2.66+/−1.67              | 0.036                 | 2.71+/−1.59       | 0.83  |
| Sleep Satisfaction   | 1.30+/−1.0      | 1.99+/−1.18              | <0.001                | 2.0+/−1.19        | 0.59  |
| Daytime Impact       | 0.94+/−0.90     | 1.51+/−1.21              | 0.003                 | 1.57+/−1.26       | 0.64  |
| QOL impact           | 0.56+/−0.75     | 1.30+/−1.10              | <0.001                | 1.28+/−1.08       | 0.47  |
| Worry about sleep    | 0.70+/−1.02     | 1.64+/−1.20              | <0.001                | 1.63+/−1.15       | 0.63  |
| Pittsburgh Sleep Quality Index Total | 4.89+/−3.38 | 7.18+/−3.80 | <0.001 | 7.12+/−3.79 | 0.52 |

ISI Insomnia Severity Index, PSQI Pittsburgh Sleep Quality Index

npj Parkinson’s Disease (2017) Published in partnership with the Parkinson’s Disease Foundation
Pittsburgh sleep quality index
A total of 111 patients and 29 controls completed the PSQI (Table 1). The total PSQI was higher in patients than controls (7.2+/−3.8 vs. 4.9+/−3.4, p = 0.004), with the proportion of abnormal PSQI higher in RBD patients than controls (68.5% vs. 44.9%, p = 0.029). On subcomponent analysis, this difference was mainly driven by the ‘sleep disturbance’ (1.49+/−0.65, vs. 1.21+/−0.56, p = 0.035) and especially ‘sleep medications’ components (1.51+/−1.43 vs. 0.28+/−0.80). These subscales query symptoms of RBD itself and possible prodromal PD (see discussion). There was no clear difference in PSQI insomnia items; however, sleep maintenance insomnia is not directly queried in the PSQI.

Of the 111 patients, 101 patients had at least one prospective follow-up visit (Fig. 1, Table 1). We found no difference in baseline PSQI scores between those who converted and those who did not (7.1+/−3.8 in converters vs. 7.7+/−4.1 in disease-free, p = 0.52). Similarly, there was no significant difference in any subcomponent between those who converted or remained disease-free.

A total of 58 patients had a follow-up PSQI, conducted a mean 2.8 years after the first PSQI (Table 2). For the entire group, there was no significant change in the total PSQI over time (change = −0.02+/−3.08 points), or in any subcomponent of the PSQI. When looking at those who converted to disease, there was no significant change in total PSQI (change = −0.82+/−3.6, p = 0.36). However, self-reported sleep duration increased significantly over time in those destined to develop disease (+0.88+/−1.32 h, p = 0.014). This change was significantly different from those who remained disease-free (disease-free = −0.02+/−1.26 h, p = 0.023). The increased duration was accompanied by a significant improvement in the PSQI sleep duration score (−0.44+/−0.66, p = 0.014) and better sleep efficiency (−0.44+/−0.81, p = 0.040), changes that were also significantly different from those patients who remained disease-free (sleep duration change in disease-free = 0.086+/−0.76, p = 0.012, efficiency change = +0.18+/−1.19, p = 0.026).

Fig. 1 Shown is the Kaplan–Meier plot of disease-free survival of patients with idiopathic RBD, stratified according to the presence of sleep abnormalities: a Sleepiness, as assessed with the ESS, b insomnia as assessed with the Insomnia Sleep Index, c general sleep disturbance, as assessed with the PSQI, and d tonic REM, stratified to greater or less than 50% of epochs. The HR is for Cox regression analysis, adjusted for age and sex.
controls (Table 3). There was no difference in sleep duration, sleep efficiency, or proportion of time spent in REM sleep between those who converted to disease vs. those who did not (Table 3, Fig. 1). Convertors had a modest decrease in % of sleep spent in REM sleep (15.8+/−8.0% vs. 19.8+/−7.5%, \( p = 0.005 \)). Also, patients who converted had higher tonic REM % (58.4+/−27.0% vs. 46.1+/−30.4%, \( p = 0.019 \), without any difference in phasic REM% (35.5+/−17.0% vs. 34.7+/−18.0%, \( p = 0.81 \)). On Cox regression analysis adjusting for age and sex, having a tonic REM > 50% was associated with a hazard ratio (HR) of 1.88 for development of neurodegenerative disease (\( p = 0.039 \)).

**Table 2. Change in Sleep Scale Scores over time**

|                    | Change: All idiopathic RBD | \( p \) | Change: converted | \( p \) |
|--------------------|---------------------------|--------|-------------------|--------|
| Epworth Sleepiness | +0.07+/−2.1               | 0.99   | +0.46+/−2.1       | 0.45   |
| Scale              | (n = 56)                  | (n = 13) |                   |        |
| Insomnia Severity  | −1.43+/−5.1               | 0.030  | −2.0+/−4.7        | 0.072  |
| Index Total        | (n = 63)                  | (n = 20) |                   |        |
| Onset Insomnia     | −0.06+/−1.10              | 0.65   | −0.15+/−1.22      | 0.59   |
| Maintenance Insomnia | −0.21+/−1.57         | 0.30   | −0.45+/−1.05      | 0.083  |
| Sleep Satisfaction | −0.33+/−1.35              | 0.056  | −0.60+/−1.43      | 0.076  |
| Daytime Impact     | −0.17+/−1.06              | 0.22   | −0.05+/−1.05      | 0.83   |
| OQL impact         | −0.17+/−1.1               | 0.21   | −0.10+/−1.2       | 0.71   |
| Worry about sleep  | −0.46+/−1.29              | 0.004  | −0.65+/−1.27      | 0.034  |
| Pittsburgh Sleep   | −0.02+/−3.08              | 0.97   | −0.82+/−3.55      | 0.36   |
| Quality Index Total| (n = 58)                  | (n = 17) |                   |        |
| Bed Time           | −0.02+/−0.48              | 0.79   | −0.06+/−0.43      | 0.58   |
| Wake Time          | +0.07+/−1.04              | 0.42   | 0.01+/−0.42       | 0.93   |
| Sleep Duration (hours) | +0.24+/−1.34         | 0.18   | +0.88+/−1.32      | 0.014  |
| Subcomponents Sleep| +0.12+/−1.30              | 0.48   | −0.18+/−1.01      | 0.47   |
| Latency            |                          |        |                   |        |
| Sleep Quality      | 0.00+/−1.01               | 1.0    | −0.059+/−1.39     | 0.86   |
| Sleep Duration     | −0.069+/−0.76             | 0.49   | −0.44+/−0.66      | 0.014  |
| Sleep Inefficiency | 0.00+/−1.13               | 1.0    | −0.44+/−0.81      | 0.040  |
| Sleep Disturbance  | −0.12+/−0.79              | 0.25   | −0.24+/−0.75      | 0.21   |
| Sleep Medications  | −0.06+/−0.73              | 0.49   | +0.35+/−1.37      | 0.31   |
| Daytime Dysfunction| −0.017+/−3.08             | 0.53   | −0.82+/−3.55      | 0.36   |

**DISCUSSION**

The key finding of this study was that although patients had mild increase in ISI and PSQI scores compared to controls, neither excessive daytime somnolence nor insomnia predicted disease outcome in patients with idiopathic RBD. On prospective follow-up, we observed over time a subtle increase in sleep duration and decreasing complaints of insomnia specifically in patients destined to develop defined neurodegenerative disease.

With regards to daytime somnolence, we found a clearly negative result. ESS scores were similar in RBD as controls, did not increase over time, and did not predict outcome in idiopathic RBD. Note that our results are in contrast to a previous study on ESS in RBD, which found elevated ESS scores and a modest degree of predictive value, such that those with scores > 8 had a faster conversion time to neurodegenerative synucleinopathy.19 We cannot easily explain the discrepancy in results. There may be population and selection differences in the cohorts, or cohorts may answer questionnaires differently.

Results of the other two scales are less clear. At baseline, we found an elevation in both PSQI and ISI scores in idiopathic RBD patients compared to controls. However, the etiology of the increase is unclear. For the PSQI, the increase was mainly driven by the sleep disturbance and sleep medication components. Note that the sleep disturbance component contains questions possibly related to RBD itself (i.e. ‘bad dreams’), and several questions that may be confounded by other prodromal PD symptoms (nocturia, pain, and temperature disturbance).22 The sleep medication component would identify medications used as primary treatment of RBD (i.e. clonazepam, melatonin) and approximately 50% were taking one of these medications at baseline. The fact that there was no increase in the components of subjective sleep quality, sleep latency, duration, efficiency or daytime dysfunction suggests that primary insomnia and somnolence on the PSQI are not abnormal in idiopathic RBD. Similarly, on the ISI, most of the elevated scores were in the general sleep disturbance/satisfaction items, which may be related to symptoms of RBD itself. However, unlike the PSQI, the ISI specifically queries sleep maintenance insomnia. Here, we found a modest increase in idiopathic RBD patients. It is possible that some sleep maintenance problems can be directly due to RBD (i.e. wakening from agitated dreams). So, in summary, we did not find unequivocal evidence that insomnia per se is a prodromal feature of PD/DLB in RBD.

With regards to polysomnographic results, we confirmed our previous report that patients with more severe REM atonia loss were at higher risk of conversion to defined neurodegeneration.14 The fact that loss of REM atonia is progressive in RBD22 might suggest that patients with higher loss are more advanced in their disease, and therefore convert sooner (note, however, that follow-up duration did not differ between converters and non-converters). As in our previous publication, only tonic REM, but not phasic REM, was associated with disease conversion. It is unclear why this difference occurs. It is possible that there is a small subset of patients diagnosed with RBD mainly because of increased phasic REM, who have a form of RBD not related to underlying neurodegenerative synucleinopathy. Given the fact that the large majority of patients in our cohort converted to neurodegenerative disease, however, this proportion is likely quite small. On polysomnogram analysis, we also saw a slightly lower proportion of time spent in REM sleep in those who converted to defined neurodegenerative disease than those who remained disease-free. These differences were modest, and the etiology unclear, particularly given that control values were intermediate between the two groups. The possibility of a spurious finding needs to be considered. It is also possible that the more severe loss of tonic REM in converters made definition of the REM Stage more difficult, thereby falsely reducing REM sleep scoring.

The assessment of evolution of sleep symptoms over time found some intriguing results. Overall, neither insomnia nor somnolence worsened over time in RBD. In contrast, insomnia scores reduced, and patients destined to develop disease reported increasing sleep duration over time. Some of the change in scales may be due to improvement in non-insomnia symptoms; for example, we have often informally noted spontaneous improvement in RBD symptoms as patients develop neurodegenerative disease. However, this should not explain the change in sleep duration. We do not think that this result from adding sedative medications. Of the 63 patients who had repeat ISI scores, 29 were taking clonazepam or melatonin at baseline, and 35 at follow-up;
therefore, only 6/63 had new sedative medications. Average doses did not change over time in those taking clonazepam or melatonin (Clonazepam dose = 0.99+/−0.68 mg/day baseline and 1.11+/−0.88 mg last follow-up, Melatonin = 5.6+/−3.3 mg/day baseline and 6.1+/−3.5 mg at follow-up). Moreover, there was no correlation between change in ISI and change in these medications (Spearman correlation co-efficient = 0.07, p = 0.59). One might speculate that a general increase in sleep drive occurs as patients approach defined neurodegenerative disease, which remains below the threshold of excessive somnolence/involuntary daytime sleep. As neurodegeneration progresses (and perhaps with addition of symptomatic PD medications), this increased drive could progress to identifiable somnolence. Further studies are required to see if somnolence itself has a prodrome of a subthreshold increase in sleep drive.

Some limitations of the study should be noted. First, sleep questionnaires were gathered in an ad-hoc clinical fashion until 2013; therefore, many patients did not have a full questionnaire panel assessed. Nevertheless, we were able to obtain at least one completed questionnaire on 80% of our participants. Second, it should be noted that not all PD/DLB patients have RBD (RBD can be found in 30–50% of PD patients and >75% of DLB patients). Because RBD marks a “diffuse-malignant” subtype of PD with increased dementia and autonomic features, and marks a subtype of DLB with decreased survival, our results cannot be reliably generalized to all PD/DLB patients. One might speculate that the RBD subtype may be more prone to somnolence rather than insomnia (given that somnolence commonly occurs in PD dementia and DLB), if so, population-based cohorts might be more likely to find sleep maintenance insomnia as a prodromal feature. Third, although the questionnaires are designed to assess specific syndromes, RBD itself can affect the way they are answered; for this reason, we took care to not simply report total scores at face value, but to look specifically within questionnaires for components that directly assessed insomnia or somnolence. Fourth, studies in idiopathic RBD may be confounded by floor effects (as we have observed in studies of autonomic dysfunction in RBD). That is, if essentially all patients with RBD are in prodromal stages of neurodegeneration and the assessed marker becomes abnormal earlier in disease than RBD, the predictive value may not be observable. However, a floor effect is very unlikely here, given that scores were mostly similar between RBD patients and controls. Fifth, we assessed multiple outcomes in this study; the findings of increased sleep duration and reduced sleep maintenance insomnia in converters were secondary variables, and should be considered as exploratory in nature. Finally, all our sleep measures are self-reported; self-reports of sleepiness in particular may be prone to underestimation by patients. It is possible that querying caregivers about somnolence would have given different results.

In conclusion, we did not find that somnolence or insomnia were prodromal markers of PD and DLB in idiopathic RBD. In RBD, there may be a subtle increase in sleep drive/duration that occurs as patients develop defined neurodegeneration.

**METHODS**

Details of the cohort, diagnostic criteria and annual follow-up protocol have been described in detail elsewhere. The study was approved by the ethics board of the Sacre Coeur hospital, and all patients gave written informed consent to participate. Briefly, all patients had idiopathic RBD, as confirmed by polysomnography. All patients were free of parkinsonism and dementia at baseline. A comprehensive baseline evaluation by a neurologist (R.B.P.), and neuropsychological examination was performed, to examine markers of prodromal PD. Patients were then followed annually with the same protocol. On follow-up, diagnosis of parkinsonism was made according to UK brain bank and MDS criteria, and the likeliest underlying diagnosis (i.e. PD or multiple system atrophy) was determined by a movement disorders specialist (R.B.P.). Dementia was diagnosed according to MDS criteria, based on a consensus between the neurologist (R.B.P.) and the neuropsychologist (J.F.G.).

Age and sex-matched control subjects were selected from our previous cohort studies. All controls had polysomnography confirming the absence of RBD, and had the same baseline evaluation performed as idiopathic RBD patients. All were free of parkinsonism or dementia. Polyomsothogram was performed according to standard protocol, with analysis of stages and quantification of REM atonia performed as described in detail elsewhere.

Three sleep measures were assessed. The ISI is a 7-item questionnaire; the first three questions directly query sleep onset and sleep maintenance insomnia, whereas the latter four query sleep satisfaction and impact of sleep disorders on quality of life. A cutoff of 10 is considered as indicating insomnia. The PSQI is a 25-item inventory that queries habitual bed time and wake time (allowing assessment of circadian rhythm disturbance), with seven additional subcomponents: subjective sleep quality, sleep latency, sleep duration, sleep efficiency, various sources of sleep disturbance, sleep medication, and daytime dysfunction (somnolence and apathy). A cutoff score of five on the total index is used to define abnormal sleep. The ESS is a test for somnolence; that quizzes the propensity to fall asleep in eight different situations. A cutoff of 10 is used to define pathologic sleepiness. We assessed these scales are part of the clinical assessment (until 2013, not all patients completed these scales). After 2013, sleep questionnaires were also assessed systematically as part of the research evaluation.

**Analysis**

For comparison to controls, the first available baseline questionnaire (always in the idiopathic RBD state) was assessed in all patients. Total scores for each scale was used as the primary analysis; secondary analysis included scale subcomponents. To assess predictive value of sleep disorders, all patients who had baseline evaluation and at least one annual follow-up examination were included. The primary analysis was for the scores as continuous variables, using student t-test. Categorical variables (i.e. proportion abnormal) were assessed with Fischer Exact test. We also assessed predictive value of sleep variables using Cox regression

### Table 3. Polysomnographic variables

|                      | Control (n = 85) | Idiopathic RBD (n = 151) | p   | Disease-free | Converted | p   |
|----------------------|-----------------|--------------------------|-----|--------------|-----------|-----|
| Sleep Latency (min)  | 19.1+/−24.4     | 23.7+/−24.8              | 0.17| 21.8+/−22.7  | 28.4+/−30.4 | 0.18|
| Total Sleep Time (min)| 383.2+/−63.4    | 384.3+/−61.7             | 0.90| 389.5+/−57.5 | 373.8+/−71.6 | 0.19|
| Sleep efficiency (%) | 79.6+/−12.3     | 81.8+/−10.6              | 0.15| 82.7+/−9.5   | 79.8+/−12.3 | 0.15|
| Stage 1 %            | 12.2+/−6.8      | 13.1+/−9.2               | 0.43| 13.1+/−8.4   | 13.8+/−11.4 | 0.71|
| Stage 2 %            | 65.5+/−9.3      | 61.9+/−11.6              | 0.015| 60.9+/−11.0  | 63.2+/−12.6 | 0.29|
| Slow wave %          | 5.4+/−8.1       | 6.5+/−8.3                | 0.33| 7.2+/−0.79   | 7.1+/−9.4   | 0.48|
| REM %                | 16.9+/−4.8      | 18.5+/−7.9               | 0.09| 19.8+/−7.5   | 15.8+/−8.0  | 0.006|
| Phasic REM density % | 11.5+/−7.9 (n = 59) | 36.6+/−17.6              | <0.001| 35.5+/−17.0  | 34.7+/−18.0 | 0.81|
| Tonic REM %          | 7.9+/−9.0 (n = 59) | 51.4+/−29.6              | <0.001| 46.1+/−30.4  | 58.4+/−27.0 | 0.019|

Published in partnership with the Parkinson’s Disease Foundation npj Parkinson’s Disease (2017)
also adjusting for age and sex. Finally, for all patients who filled out repeated questionnaires, we assessed change over time comparing the most recently-measured scores to baseline, using one-sample t-test (we analyzed polysomnogram variables at baseline only).

ACKNOWLEDGEMENTS
This study was funded by the Canadian Institutes of Health Research, the Webster Foundation and the Fonds de la Recherche en Santé du Québec–Santé.

AUTHOR CONTRIBUTIONS
Dr. R.B.P: study concept and design, analysis and interpretation, writing the original version; Dr. J.F.G: analysis and interpretation, critical revision of the manuscript for important intellectual content; Dr. A.P: acquisition of data, critical revision of the manuscript for important intellectual content; Dr. J.Y.M: study concept and design, study supervision, critical revision of the manuscript for important intellectual content.

COMPETING INTERESTS
R.B.P. received grants from the Fonds de Recherche du Québec—Santé, the Canadian Institute of Health Research, the Parkinson Society of Canada, the Michael J. Fox Foundation, and the Webster Foundation, as well as funding for consultancy from Biote and Roche and speaker fees from Biogen and Teva Neurosciences. J.F.G. received grants from the Fonds de Recherche du Québec—Santé, the W. Garfield Weston Foundation, and the Canadian Institutes of Health Research. He holds a Canada Research Chair in Cognitive Decline in Pathological Aging. A.P. has nothing to disclose. J.Y.M. received personal compensation as consultant (Impax pharma, Servier,Jazz pharma, Merck, Valeant), speaker (Valeant), and received financial support for research activities from Merck, GlaxoSmithKline is funded by grants from the Fonds de la Recherche du Québec—Santé, and by the Canadian Institutes of Health Research. The authors have no competing interests to disclose in relation to this manuscript.

REFERENCES
1. Ratti, P. L. et al. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat. Disord. 21, 1323–1329 (2015).
2. Arnulf, I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9, 185–200 (2005).
3. Abbott, R. D. et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65, 1442–1446 (2009).
4. Gao, J. et al. Daytime napping, nighttime sleeping, and Parkinson disease. Am. J. Epidemiol. 173, 1032–1038 (2011).
5. Simuni, T. et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study. Mov. Disord. 30, 1371–1381 (2015).
6. Breen, D. P. et al. Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 84, 233–234 (2013).
7. Schrag, A., Horsfall, L., Walters, K., Noyce, A. & Petersen, I. Predictive presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 14, 57–64 (2015).
8. Berg, D. et al. MDS research criteria for prodromal Parkinson’s disease. Mov. Disord. 30, 1600–1611 (2015).
9. Schenck, C. H., Boeve, B. F. & Mahowald, M. W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 14, 744–748 (2013).
10. Iranzo, A. et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 9, e89741 (2014).
11. Postuma, R. B. et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72, 1296–1300 (2009).
12. Iranzo, A. et al. Decreased striatal dopaminergic transporters uptake and substantia nigra hyperchogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9, 1070–1077 (2010).
13. Postuma, R. B. et al. Flaccion and color vision identify impending neurodegeneration in REM behavior disorder. Ann. Neurol. 69, 811–818 (2011).
14. Postuma, R. B., Gagnon, J. F., Rompre, S. & Montplaisir, J. Severity of REM atonia loss in idiopathic REM Sleep behavior disorder predicts Parkinson disease. Neurology 74, 239–244 (2010).
15. Ferini-Strambi, L. et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. J. Neurol. 261, 1112–1118 (2014).
16. Postuma, R. B. et al. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135, 1860–1870 (2012).
17. Rodrigues-Brazete, J. et al. Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. Neurobiol. Aging. 37, 74–81 (2016).
18. Mahlknecht, P. et al. Offactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84, 654–658 (2015).
19. Arnulf, I. et al. Sleepiness in idiopathic REM sleep behavior disorder and Parkinson disease. Sleep 38, 1529–1535 (2015).
20. Postuma, R. B. et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84, 1104–1113 (2015).
21. Postuma, R. B. et al. MDS Clinical diagnostic criteria for Parkinson’s disease. Mov. Disord 30, 1591–1600 (2015).
22. Goldman, J. G. & Postuma, R. Premotor and nonmotor features of Parkinson’s disease. Curr. Opin. Neuro 27, 434–441 (2014).
23. Iranzo, A. et al. Excessive muscular activity increases over time in idiopathic REM sleep behavior disorder. Sleep 32, 1149–1153 (2009).
24. Gagnon, J. F. et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology 59, 585–589 (2002).
25. Sixel-Doring, F., Trautmann, E., Molleenhauer, B. & Trenkwalder, C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 77, 1048–1054 (2011).
26. Ferman, T. J. et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 77, 875–882 (2011).
27. Fereshetian, S. M. et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 72, 863–873 (2015).
28. Anang, J. B. et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83, 1253–1260 (2014).
29. Dugger, B. N. et al. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov. Disord 27, 72–78 (2011).
30. Postuma, R. B., Gagnon, J. F., Pelletier, A. & Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov. Disord 28, 597–604 (2013).
31. Postuma, R. B., Lanfranchi, P. A., Blais, H., Gagnon, J. F. & Montplaisir, J. Y. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov. Disord 25, 2304–2310 (2011).
32. Bender, R. & Lange, S. Adjusting for multiple testing—when and how? J. Clin. Epidemiol. 54, 343–349 (2009).
33. Merino-Andreu, M., Arnulf, I., Konofal, E., Derenne, J. P. & Agid, Y. Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness. Neurology 60, 1553–1554 (2003).
34. Postuma, R. B., Lang, A. E., Massicotte-Marquez, J. & Montplaisir, J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66, 845–851 (2006).
35. Postuma, R. B., Gagnon, J. F., Vendette, M. & Montplaisir, J. Markers of neurodegeneration in Idiopathic REM Sleep behavior disorder and Parkinson disease. Brain 132, 2298–2307 (2009).
36. Montplaisir, J. et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov. Disord 25, 2044–2051 (2010).
37. Gibb, W. R. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 51, 745–752 (1988).
38. Dubois, B. et al. Diagnostic procedures for Parkinson’s disease: recommendations from the movement disorder society task force. Mov. Disord 22, 2314–2324 (2007).
39. Basten, C. H., Vallieres, A. & Morin, C. M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2, 297–307 (2001).
40. Buysse, D. J. et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213 (1989).
41. Johns, M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14, 540–545 (1991).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017

Published in partnership with the Parkinson’s Disease Foundation